1. Home
  2. PNR vs INCY Comparison

PNR vs INCY Comparison

Compare PNR & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pentair plc.

PNR

Pentair plc.

HOLD

Current Price

$87.48

Market Cap

14.4B

Sector

Industrials

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$92.21

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNR
INCY
Founded
1966
1991
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Commercial Physical & Biological Resarch
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.4B
17.0B
IPO Year
2003
1994

Fundamental Metrics

Financial Performance
Metric
PNR
INCY
Price
$87.48
$92.21
Analyst Decision
Buy
Buy
Analyst Count
14
21
Target Price
$116.62
$100.76
AVG Volume (30 Days)
1.3M
1.4M
Earning Date
04-21-2026
04-28-2026
Dividend Yield
1.23%
N/A
EPS Growth
5.88
4173.33
EPS
3.96
6.41
Revenue
N/A
$3,394,635,000.00
Revenue This Year
$4.21
$10.97
Revenue Next Year
$4.83
$10.48
P/E Ratio
$22.14
$14.14
Revenue Growth
N/A
13.67
52 Week Low
$74.25
$53.56
52 Week High
$113.95
$112.29

Technical Indicators

Market Signals
Indicator
PNR
INCY
Relative Strength Index (RSI) 32.08 39.86
Support Level N/A $82.66
Resistance Level $108.26 $92.86
Average True Range (ATR) 2.51 2.27
MACD -0.08 -0.18
Stochastic Oscillator 15.05 36.01

Price Performance

Historical Comparison
PNR
INCY

About PNR Pentair plc.

Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: